Patents by Inventor Daniel J. Dairaghi
Daniel J. Dairaghi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7262204Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.Type: GrantFiled: September 2, 2003Date of Patent: August 28, 2007Assignees: Amgen Inc., ChemoCentryx, Inc.Inventors: Tassie Collins, Daniel J. Dairaghi, Hossen Mahmud, Brian E. McMaster, Julio C. Medina, Thomas J. Schall, Feng Xu, Xuemei Wang
-
Patent number: 7132508Abstract: A novel CC chemokine which is from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokine. A chemokine receptor is also provided. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: November 13, 2002Date of Patent: November 7, 2006Assignee: Schering CorporationInventors: Daniel J. Dairaghi, Takahiko Hara, Atsushi Miyajima, Thomas J. Schall, Wei Wang, Akihiko Yoshimura
-
Patent number: 7108990Abstract: The invention provides polypeptides and polynucleotides encoding a novel chemokine receptor, CCX CKR. The invention further provides reagents and methods for identifying agents that modulate the activity or expression of the receptors, as well as methods for detecting receptor expression.Type: GrantFiled: February 24, 2004Date of Patent: September 19, 2006Assignee: ChemoCentryx, Inc.Inventors: Jennifa Gosling, Daniel J. Dairaghi, Michael Hanley, Zhenhua Miao, Thomas J. Schall
-
Patent number: 7101894Abstract: Methods for treating CMV or a CMV-related disease are provided that use compounds having the formula: wherein Ar is a substituted or unsubstituted 5–14 membered heteroaryl group having from 1 to 5 heteroatoms as ring members; R1 is selected from the group consisting of substituted or unsubstituted aryl(C1–C4)alkyl, heteroaryl(C1–C4)alkyl, —C(O)R11, and —C(O)NR11R12, wherein each R11 and R12 independently is substituted or unsubstituted aryl, substituted or unsubstituted aryl(C1–C4)alkyl, substituted or unsubstituted (C4–C8)cycloalkyl(C1–C4)alkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl(C1–C4)alkyl and substituted or unsubstituted hetero(C4–C8)cycloalkyl(C1–C4)alkyl; R2 is H or (C1–C8)alkyl; and ZN is a substituted or unsubstituted hetero(C6–C10)bicycloalkyl group.Type: GrantFiled: August 29, 2002Date of Patent: September 5, 2006Assignee: ChemoCentryx, Inc.Inventors: Brian E. McMaster, Thomas J. Schall, Mark Penfold, J. J. Wright, Daniel J. Dairaghi
-
Patent number: 6998239Abstract: The invention provides polypeptides and polynucleotides encoding a novel chemokine receptor, CCX CKR. The invention further provides reagents and methods for identifying agents that modulate the activity or expression of the receptors, as well as methods for detecting receptor expression.Type: GrantFiled: November 21, 2000Date of Patent: February 14, 2006Assignee: ChemoCentryx, Inc.Inventors: Jennifa Gosling, Daniel J. Dairaghi, Michael Hanley, Zhenhua Miao, Dale Talbot, Thomas J. Schall
-
Patent number: 6992084Abstract: The invention provides compounds and compositions of the formula: wherein, the subscript n is an integer of from 0 to 4; Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl, R1 is a member selected from the group consisting of substituted or unsubstituted (C5–C15)alkyl and (C8–C14)acyl group; R2 is a member selected from the group consisting of substituted or unsubstituted (C1–C8)alkyl; each R3 is independently a substituent Y is a member selected from the group consisting of substituted or unsubstituted (C2–C8)alkylene and substituted or unsubstituted (C2–C8)heteroalkylene; Z is —NR4R5 R4 and R5 are independently selected from the group consisting of hydrogen and (C1–C8)alkyl or taken together with the nitrogen atom to which each is attached to form a heterocyclyl or heteroaryl; These compounds and compositions bind to the CXCR3 chemokine receptor and are useful for treating diseases and conditions responsive to the moType: GrantFiled: October 23, 2002Date of Patent: January 31, 2006Assignee: ChemoCentryx, Inc.Inventors: Thomas J. Schall, Daniel J. Dairaghi, Brian E. McMaster
-
Patent number: 6835547Abstract: The invention provides polypeptides and polynucleotides encoding a novel chemokine receptor, CCX CKR. The invention further provides reagents and methods for identifying agents that modulate the activity or expression of the receptors, as well as methods for detecting receptor expression.Type: GrantFiled: November 21, 2000Date of Patent: December 28, 2004Assignee: ChemoCentryx, Inc.Inventors: Jennifa Gosling, Daniel J. Dairaghi, Michael Hanley, Zhenhua Miao, Dale Talbot, Thomas J. Schall
-
Patent number: 6821998Abstract: Methods for treating CMV and CMV-related diseases are provided that use compounds having the formula: wherein the subscripts m and n are each independently integers from 1 to 2; and the R groups are as defined in the specification.Type: GrantFiled: August 29, 2002Date of Patent: November 23, 2004Assignee: ChemoCentryx, Inc.Inventors: Brian E. McMaster, Thomas J. Schall, Mark Penfold, J. J. Wright, Daniel J. Dairaghi
-
Publication number: 20040146926Abstract: The invention provides polypeptides and polynucleotides encoding a novel chemokine receptor, CCX CKR. The invention further provides reagents and methods for identifying agents that modulate the activity or expression of the receptors, as well as methods for detecting receptor expression.Type: ApplicationFiled: February 24, 2004Publication date: July 29, 2004Applicant: ChemoCentryx, Inc.Inventors: Jennifa Gosling, Daniel J. Dairaghi, Michael Hanley, Zhenhua Miao, Dale Talbot, Thomas J. Schall
-
Publication number: 20040039035Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.Type: ApplicationFiled: September 2, 2003Publication date: February 26, 2004Applicants: Tularik Inc., ChemoCentryx, Inc.Inventors: Tassie Collins, Daniel J. Dairaghi, Hossen Mahmud, Brian E. McMaster, Julio C. Medina, Thomas J. Schall, Feng Xu, Xuemei Wang
-
Publication number: 20030149055Abstract: Methods for treating CMV or a CMV-related disease are provided that use compounds having the formula: 1Type: ApplicationFiled: August 29, 2002Publication date: August 7, 2003Applicant: ChemoCentryxInventors: Brian E. McMaster, Thomas J. Schall, Mark Penfold, J. J. Wright, Daniel J. Dairaghi
-
Publication number: 20030130494Abstract: A novel CC chemokine which is from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokine. A chemokine receptor is also provided. Methods of using said reagents and diagnostic kits are also provided.Type: ApplicationFiled: November 13, 2002Publication date: July 10, 2003Inventors: Daniel J. Dairaghi, Takahiko Hara, Atsushi Miyajima, Thomas J. Schall, Wei Wang, Akihiko Yoshimura
-
Publication number: 20030119854Abstract: Compounds and compositions are provided that bind to the CXCR3 chemokine receptor and which are useful for treating diseases associated with CXCR3 activity, such as multiple sclerosis.Type: ApplicationFiled: October 23, 2002Publication date: June 26, 2003Applicant: ChemoCentryx, Inc.Inventors: Thomas J. Schall, Daniel J. Dairaghi, Brian E. McMaster
-
Publication number: 20030114423Abstract: Methods for treating CMV and CMV-related diseases are provided that use compounds having the formula: 1Type: ApplicationFiled: August 29, 2002Publication date: June 19, 2003Applicant: ChemoCentryx, Inc.Inventors: Brian E. McMaster, Thomas J. Schall, Mark Penfold, J.J. Wright, Daniel J. Dairaghi
-
Patent number: 6559160Abstract: The invention provides compounds and compositions of the formula: wherein the subscript n is an integer of from 0 to 4; Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; R1 is a member selected from the group consisting of substituted or unsubstituted (C5-C15)alkyl; R2 is a member selected from the group consisting of substituted or unsubstituted (C1-C8)alkyl; each R3 is independently a substituent selected from -halogen, —OR′, —OC(O)R′, —NR′R″, —SR′, —R′, —CN, —NO2, —CO2R′, —CONR′R″, —C(O)R′, —OC(O)NR′R″, —NR″C(O)R′, —NR″C(O)2R′, , —NR′—C(O)NR″R′″, —NH—C(NH2)═NH, —NR′C(NH2)═NH, —NH—C(NH2)═NR—, —S(O)R′, —S(O)2R′, —Type: GrantFiled: August 25, 2000Date of Patent: May 6, 2003Assignee: Chemocentryx, Inc.Inventors: Thomas J. Schall, Daniel J. Dairaghi, Brian E. McMaster
-
Patent number: 6512103Abstract: A novel CC chemokine which is from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokine. A chemokine receptor is also provided. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: December 8, 1995Date of Patent: January 28, 2003Assignee: Schering CorporationInventors: Daniel J. Dairaghi, Takahiko Hara, Atsushi Miyajima, Thomas J. Schall, Wei Wang, Akihiko Yoshimura
-
Publication number: 20020193374Abstract: Methods are provided for detecting the spread of cytomegalovirus in a host infected with CMV, by administering to the host a detectable and labeled amount of a non-endogenous compound which binds to US28 or a US28 fragment. Typically, the methods use a labeled form of IBZM.Type: ApplicationFiled: August 30, 2001Publication date: December 19, 2002Applicant: ChemoCentryxInventors: Thomas J. Schall, Brian E. McMaster, Daniel J. Dairaghi
-
Publication number: 20020173524Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.Type: ApplicationFiled: October 11, 2001Publication date: November 21, 2002Applicant: Tularik Inc.Inventors: Tassie Collins, Daniel J. Dairaghi, Hossen Mahmud, Brian E. McMaster, Julio C. Medina, Thomas J. Schall, Feng Xu, Xuemei Wang
-
Publication number: 20020132836Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.Type: ApplicationFiled: October 11, 2001Publication date: September 19, 2002Applicant: ChemoCentryx Inc.Inventors: Daniel J. Dairaghi, Brian E. McMaster, Thomas J. Schall
-
Patent number: RE39849Abstract: The invention provides polypeptides and polynucleotides encoding a novel chemokine receptor, CCX CKR. The invention further provides reagents and methods for identifying agents that modulate the activity or expression of the receptors, as well as methods for detecting receptor expression.Type: GrantFiled: December 29, 2005Date of Patent: September 18, 2007Assignee: ChemoCentryx, Inc.Inventors: Jennifa Gosling, Daniel J. Dairaghi, Michael Hanley, Zhenhua Miao, Thomas J. Schall